In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Potomac Pharma, Inc.

Latest From Potomac Pharma, Inc.

Business & Technology Briefs (08/2007)

Brief summaries of recent product and company developments in the device industry, including the demise of GE's proposed $8 billion acquisition of Abbott Diagnosticss, the Cytyc/Hologic merger, and Alsius' SPAC merger.

Potomac Pharmaceuticals Inc.

Off-label use of multiple drugs has become a widespread clinical practice in treating schizophrenia. Potomac Pharma Inc. aims to improve outcomes by developing a highly selective alpha-2 antagonists for adjunctive use in treating neurological and psychiatric disorders.

BioPharmaceutical Platform Technologies

Building a Better Drug for Schizophrenia

Start-ups in pursuit of novel targets are capturing the attention of venture capitalists.

BioPharmaceutical Strategy

Start-Up Previews (4/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Building a Better Drug for Schizophrenia, features profiles of Galenea Corp., Potomac Pharma Inc., Vanda Pharmaceuticals Inc. and Xytis Pharmaceuticals Ltd. Plus these Start-Ups Across Health Care: Aqueduct Medical Inc., CryoFluor Therapeutics LLC, 3DM Inc. and Xigen SA.

See All

Company Information

  • Industry
  • Pharmaceuticals